Drug Profile
Doxorubicin encapsulated nanocells - EnGeneIC
Alternative Names: EGFREDVDox; Doxorubicin packaged EDV™ nanocells - EnGeneIC; Doxorubicin-loaded EDV nanocells; EGFR(V)-EDV-Dox; EnGeneIC Delivery Vehicle™; EnGeneIC Dream Vector™; VEDVDoxLatest Information Update: 14 Jan 2022
Price :
$50
*
At a glance
- Originator EnGeneIC
- Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Small molecules
- Mechanism of Action Immunostimulants; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Glioblastoma
- No development reported Brain cancer; Solid tumours
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for phase-I development in Solid-tumours(Treatment-naive) in Australia (IV)
- 28 May 2020 No recent reports of development identified for preclinical development in Brain-cancer(Late-stage disease) in Australia
- 28 Mar 2020 No recent reports of development identified for phase-I development in Glioblastoma(Late-stage disease, Recurrent, Second-line therapy or greater) in USA (IV, Infusion)